Aktuellt
SENASTE
We raise our sales estimates by 2% for 2024-26 ahead of Q3. With first meaningful sales in orthobiologics two years ago, we conclude OssDsign remains at an early commercialisation stage with the cranial implants discontinued. With LTM sales at SEK 100m, uptake is fast and gross margins have improved substantially (>93% in H1). We are confident that strong growth can continue, and instead flag operating leverage as a key uncertainty.
LÄS MER
